Cancer Risk: Groundbreaking Blood Test allows Early Detection

Join us for this special seminar which will highlight a groundbreaking blood test for early detection and monitoring of cancer risk.

Special International Speaker
Prof Patrizia Paterlini-Brechot, founder of ISET-CTC test will outline the technology and its applications.

Michael Navybox, Cancer Survivor will share his inspirational story involving CTC testing

A/Prof Karin Ried, NIIM Research Director will summarise findings of the ISET-CTC test at NIIM, the first institute in Australia to offer ISET-CTC testing since 2014.

WHEN: Tuesday 2 October 6.30pm – 8.00pm

LOCATION:
NIIM Lecture Theatre
Level 3, 21 Burwood Rd, Hawthorm, Victoria 3122

Featuring:

International guest speaker from France
Prof Patrizia Paterlini-Brechot
Founder of Rarecells Diagnostics, who developed the groundbreaking Circulating Tumour Cell (CTC) Blood Test, using the cytology-based Isolation by Size of Epithelial Tumour Cells (ISET) technique. Professor of Cell Biology and Oncology at the Université Paris Descartes and at INSERM in Paris.

Michael Navybox
Entrepreneur, elite athlete, driving coach and cancer survivor. Mike has achieved success in many fields yet his greatest achievement to-date is the one against cancer.

A/Professor Karin Ried
PhD MSc GDPH Cert.Integ.Med
Director of Research at NIIM, with over 20 years’ experience in medical & public health research. Karin has a PhD & Masters Degree from the University of Heidelberg, Germany, Dept of Human Molecular Genetics. Her research projects encompass nutritional medicine, cardiovascular and brain health, chronic diseases and cancer.

Publication: Ried Karin, Eng Peter, Sali Avni. Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study. Asian Pac J Cancer Prevention (APJCP) 2017;18(8):2275.https://journal.waocp.org/article_49378.html